用R-GemOx治疗的复发性或耐火性扩散性大B细胞淋巴瘤的结果:一个多中心队列研究
Samuel Yamshon1, Jean L Koff2, Melissa C Larson3
1Division of Hematology and Medical Oncology, Weill Cornell Medicine, New York, New York, USA.
American journal of hematology
|February 7, 2025
概括
利图西马布,格姆西塔和氧沙 (R-GemOx) 在复发性或耐火性扩散性大B细胞淋巴瘤 (DLBCL) 中表现出中度的有效性. 当R-GemOx被用作移植或老年患者的桥梁时,结果会有所不同.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 临床试验 临床试验
背景情况:
- 利图西马布,格姆西塔和氧沙 (R-GemOx) 是用于复发性或耐火性 (R/R) 扩散性大B细胞淋巴瘤 (DLBCL) 的标准化疗免疫疗法.
- 对于R/R DLBCL中的R-GemOx存在有限的现实数据,特别是在不同的治疗策略和患者人口统计学中.
研究的目的:
- 评估R-GemOx在大量R/R DLBCL和高级B细胞淋巴瘤患者队列中的实际有效性.
- 根据治疗意图 (例如,移植与独立治疗之间的桥梁) 和患者年龄 (≥70岁) 来分析结果.
主要方法:
- 一项多中心回顾性研究,涉及183名R/R DLBCL患者,在美国八个学术中心 (LEO CReWE) 用R-GemOx治疗.
- 对未被用于自身干细胞移植 (ASCT) 或CAR T细胞治疗 (n=100) 的患者,使用R-GemOx作为ASCT或CAR T的桥梁 (n=83),以及老年患者 (≥70岁,n=71) 进行了子组分析.
主要成果:
- 所有患者的整体响应率 (ORR) 为45%,完全响应率 (CR) 为29%. 无事件生存 (EFS) 的中位数为2.3个月,总生存 (OS) 的中位数为13.5个月.
- 与没有接受整合治疗的患者相比,接受R-GemOx作为通往ASCT或CAR T的桥梁的患者的ORR (57%) 和CR (36%) 率较高,EFS (3.5个月) 和OS (17.4个月) 中位数改善.
- 老年患者 (≥70岁) 的ORR为53%,CR为33%,EFS中位数为2.2个月,OS为13.9个月,表明结果与整体队列相似.
结论:
- R-GemOx在R/R DLBCL中表现出适度的疗效,其结果受到其作为桥梁对ASCT或CAR T细胞疗法等潜在治疗疗法的使用的影响.
- 该方案在老年患者中看起来可行和有效,在这个人群中提供了有价值的治疗选择.
- 这些现实数据为R-GemOx在R/R DLBCL不断变化的治疗环境中建立了基准.
更多相关视频
05:32Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
Published on: January 7, 2019
6.8K
10:27Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
7.2K
相关概念视频
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
01:15Secondary Lymphoid Organs
Secondary organs, including lymph nodes, the spleen, and mucosa-associated lymphoid tissue (MALT), work harmoniously to protect us from disease and infection.
The spleen is a vital organ in the lymphatic system, nestled in the upper left side of the abdomen. It is composed of two primary regions: the red pulp and the white pulp, each having distinct functions. The red pulp performs a significant role in blood filtration. It efficiently purges the blood of old or damaged red blood cells and...
The spleen is a vital organ in the lymphatic system, nestled in the upper left side of the abdomen. It is composed of two primary regions: the red pulp and the white pulp, each having distinct functions. The red pulp performs a significant role in blood filtration. It efficiently purges the blood of old or damaged red blood cells and...